Company
Board of Directors
Göran Ando, MD
Chairman of the Board of Directors, Chairman of the Remuneration Committee and member of the Development Committee
Göran Ando has been Chairman of the Board since 2011.
Dr. Ando is a specialist in g… Read moreeneral medicine and a founding fellow of the American College of Rheumatology in the US.
Dr. Ando serves as a board member of Tessa Therapeutics, Singapore, Molecular Partners AG, Switzerland, EUSA Pharma Ltd., UK, Parexel, US and ICMEC, US. Dr Ando also serves as a Senior Advisor to EW Healthcare Partners.
Dr. Ando's special competencies with relevance for Symphogen include medical qualifications and extensive executive background within the international pharmaceutical industry.
Dr. Ando is a specialist in g… Read moreeneral medicine and a founding fellow of the American College of Rheumatology in the US.
Dr. Ando serves as a board member of Tessa Therapeutics, Singapore, Molecular Partners AG, Switzerland, EUSA Pharma Ltd., UK, Parexel, US and ICMEC, US. Dr Ando also serves as a Senior Advisor to EW Healthcare Partners.
Dr. Ando's special competencies with relevance for Symphogen include medical qualifications and extensive executive background within the international pharmaceutical industry.
Kirsten Drejer, Cand.pharm and Ph.D.
Board member, member of the Development Committee
Kirsten Drejer is co-founder of Symphogen and served as the CEO of Symphogen in the period 2000-2016… Read more, in which period she was also a member of the Board.
Dr. Drejer serves as Chairman of the Board of Bioneer A/S and as board member of Zealand Pharma, Resother Pharma, The Fund for Industrial Growth, Bioporto and Lyhne & Co
Dr. Drejer's special competencies with relevance for Symphogen include executive management, as well as research and development in the biopharmaceutical industry.
Dr. Drejer serves as Chairman of the Board of Bioneer A/S and as board member of Zealand Pharma, Resother Pharma, The Fund for Industrial Growth, Bioporto and Lyhne & Co
Dr. Drejer's special competencies with relevance for Symphogen include executive management, as well as research and development in the biopharmaceutical industry.
Ron Eastman, MBA
Board member, member of the Remuneration Committee and the Audit Committee
Ron Eastman has been a member of the Board since 2015.
Mr. Eastman is Managing Direc… Read moretor of EW Healthcare Partners.
He serves as Chairman of EluSys Therapeutics Inc, and is a member of the board of Corium International and IntegenX.
Mr. Eastman's special competencies with relevance for Symphogen include executive and board experience with special focus on building healthcare businesses.
Mr. Eastman is Managing Direc… Read moretor of EW Healthcare Partners.
He serves as Chairman of EluSys Therapeutics Inc, and is a member of the board of Corium International and IntegenX.
Mr. Eastman's special competencies with relevance for Symphogen include executive and board experience with special focus on building healthcare businesses.
Jeppe Christiansen, M.Sc.
Board member, member of the Remuneration Committee
Jeppe Christiansen has been a member of the Board since 2011.
He is CEO at Fondsmægl… Read moreerselskabet Maj Invest A/S, Maj Invest Holding A/S and Emlika ApS. He is also a member of the Executive Management of Maj Invest Equity A/S.
Mr. Christiansen serves as Chairman of Haldor Topsøe A/S, and Vice-Chairman of Novo Nordisk A/S and Maj Bank A/S. He is a board member of Novo Holdings A/S, KIRK- BI A/S, and member of the Board of Governors at Det Kgl. Vajsenhus.
Mr. Christiansen's special competencies with relevance for Symphogen include executive background and extensive experience within the financial sector in relation to financial and capital market issues as well as insight into the investor perspective.
He is CEO at Fondsmægl… Read moreerselskabet Maj Invest A/S, Maj Invest Holding A/S and Emlika ApS. He is also a member of the Executive Management of Maj Invest Equity A/S.
Mr. Christiansen serves as Chairman of Haldor Topsøe A/S, and Vice-Chairman of Novo Nordisk A/S and Maj Bank A/S. He is a board member of Novo Holdings A/S, KIRK- BI A/S, and member of the Board of Governors at Det Kgl. Vajsenhus.
Mr. Christiansen's special competencies with relevance for Symphogen include executive background and extensive experience within the financial sector in relation to financial and capital market issues as well as insight into the investor perspective.
Jeffrey H. Buchalter, MBA
Board member, Chairman of the Audit Committee and member of the Development Committee
Jeffrey H. Buchalter has been a member of the Board since 2016.
He is Chairman and CE… Read moreO of KBS Healthcare Consulting.
Mr. Buchalter serves as Chairman of Inivata, and he is a board member of Molecular Partners.
Mr. Buchalter's special competencies with relevance for Symphogen include global commercial and drug development experience in oncology and other therapeutic areas.
He is Chairman and CE… Read moreO of KBS Healthcare Consulting.
Mr. Buchalter serves as Chairman of Inivata, and he is a board member of Molecular Partners.
Mr. Buchalter's special competencies with relevance for Symphogen include global commercial and drug development experience in oncology and other therapeutic areas.
John B. Landis, Ph.D.
Board member, Chairman of the Development Committee
John B. Landis has been a member of the Board since 2011.
He is a Director at Exelea… Read mored.
Mr. Landi's special competencies with relevance for Symphogen include scientific and corporate background in pharmacy, analytical chemistry, process chemistry, biotechnology, quality assurance, and clinical supplies and devices.
He is a Director at Exelea… Read mored.
Mr. Landi's special competencies with relevance for Symphogen include scientific and corporate background in pharmacy, analytical chemistry, process chemistry, biotechnology, quality assurance, and clinical supplies and devices.
Christoffer Søderberg, M.Sc.
Board member, member of the Audit Committee
Christoffer Søderberg has been a member of the Board since 2016.
He is Senior Direct… Read moreor Principal Investments at Novo Holdings A/S.
He serves as a board member of Cidron Healthcare – IT 2 Limited.
Mr. Søderberg's special competencies with relevance for Symphogen include investments and capital market transactions.
He is Senior Direct… Read moreor Principal Investments at Novo Holdings A/S.
He serves as a board member of Cidron Healthcare – IT 2 Limited.
Mr. Søderberg's special competencies with relevance for Symphogen include investments and capital market transactions.
Anders Tullgren
Board member, member of the Development Committee
Anders Tullgren was elected member of the Board in April 2018.
Mr. Tullgren current… Read morely serves as Chairman of Xbrane Biopharma and Trialbee AB, Sweden and is a board member of Branding Science Ltd, UK.
Mr. Tullgren's special competencies with relevance for Symphogen include his proven commercial and leadership experiences from 30 years in global pharmaceutical industries.
Mr. Tullgren current… Read morely serves as Chairman of Xbrane Biopharma and Trialbee AB, Sweden and is a board member of Branding Science Ltd, UK.
Mr. Tullgren's special competencies with relevance for Symphogen include his proven commercial and leadership experiences from 30 years in global pharmaceutical industries.
Martin Olin
Chief Executive Officer
Reference is made to the section “Executive Management”.